Curanex Pharmaceuticals (CURX) vs FibroBiologics (FBLG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Curanex Pharmaceuticals is the larger company by market cap ($8.3 million vs $8.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CURX | FBLG |
|---|---|---|
| Share price | $5.31 | $1.13 |
| Market cap | $8.33M | $8.00M |
| 1-day change | +11.55% | +1.80% |
| EPS (TTM) | $-7.80 | $-5.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.94 | $9.66 |
| 52-week low | $3.58 | $0.62 |
| Distance from 52-week high | -68.65% | -88.30% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +1006.19% |
| Average volume | 20.04K | 206.10K |
| Shares outstanding | 1.57M | 7.08M |
| Employees | 6 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Curanex Pharmaceuticals
CURX stock →Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About FibroBiologics
FBLG stock →FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
CURX vs FBLG FAQ
Which is bigger, Curanex Pharmaceuticals or FibroBiologics?
Curanex Pharmaceuticals (CURX) is larger, with a market capitalization of $8.33M compared with $8.00M for FibroBiologics (FBLG).
Are Curanex Pharmaceuticals and FibroBiologics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.